Sangui Biotech International, Inc.

OTCPK:SGBI Stock Report

Market Cap: US$446.6k

Sangui Biotech International Past Earnings Performance

Past criteria checks 0/6

Sangui Biotech International has been growing earnings at an average annual rate of 23.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 7.3% per year.

Key information

23.2%

Earnings growth rate

24.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate7.3%
Return on equityn/a
Net Margin-104.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sangui Biotech International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:SGBI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230000
30 Sep 230000
30 Jun 230000
31 Mar 230000
31 Dec 220000
30 Sep 220000
30 Jun 220000
31 Mar 220000
31 Dec 210000
30 Sep 210000
30 Jun 210000
31 Mar 210000
31 Dec 200000
30 Sep 200000
30 Jun 200000
31 Mar 200000
31 Dec 190000
30 Sep 190000
30 Jun 190000
31 Mar 190000
31 Dec 180000
30 Sep 180000
30 Jun 180000
31 Mar 180000
31 Dec 170000
30 Sep 170000
30 Jun 170000
31 Mar 170000
31 Dec 160000
30 Sep 160000
30 Jun 160000
31 Mar 160-100
31 Dec 150-110
30 Sep 150-110
30 Jun 150-110
31 Mar 150-101
31 Dec 140-111
30 Sep 140-111
30 Jun 140-111
31 Mar 140-310
31 Dec 130-210
30 Sep 130-210
30 Jun 130-210

Quality Earnings: SGBI is currently unprofitable.

Growing Profit Margin: SGBI is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SGBI is unprofitable, but has reduced losses over the past 5 years at a rate of 23.2% per year.

Accelerating Growth: Unable to compare SGBI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGBI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).

Return on Equity

High ROE: SGBI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/15 19:35
End of Day Share Price 2024/01/17 00:00
Earnings2023/12/31
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sangui Biotech International, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution